Opinion of the Transparency Council – leflunomide
At its meeting on 9 June 2025, the Transparency Council adopted opinion No. 101/2025 on the reimbursement of medicines containing the active substance leflunomide for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics, i.e. juvenile idiopathic arthritis